SUVEN LIFE SCIENCES LTD, WO 2016178064, POLYMORPH OF NINTEDANIB ETHANESULPHONATE, NEW PATENT

It's only fair to share...Flattr the authorPin on PinterestEmail this to someone
Buffer this pageDigg thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInShare on YummlyShare on VKShare on RedditShare on StumbleUponPrint this pageShare on Tumblr

NINTEDANIB ETHANESULPHONATE

NEW PATENT

WO2016178064, CLICK FOR PATENT

POLYMORPH OF NINTEDANIB ETHANESULPHONATE, PROCESSES AND INTERMEDIATES THEREOF

SUVEN LIFE SCIENCES LIMITED [IN/IN]; 5th floor, Serene Chamber, Road No.5, Off Avenue No. 7, Banjara Hills, Telangana Hyderabad 500034 (IN)

ARAVA, Veera Reddy; (IN).
GOGIREDDY, Surendra Reddy; (IN).
JASTI, Venkateswarlu; (IN)

DR VEERA ARAVA REDDY

Image result for suven life sciences

Veerareddy Arava

Vice President

Surendra Reddy Gogireddy, Sr.Research Associate

JASTI, Venkateswarlu

The present invention provides novel crystalline Form of Nintedanib and process for its preparation. The present invention also provides to a novel process for the preparation of Nintedanib. The present invention further provides to novel intermediates used in the preparation of Nintedanib and process for their preparation.

Image result for suven life sciences

Nintedanib inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).The chemical name of Nintedanib is lH-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl-(4-methyl-l-iperazinyl)acetyl]amino]phenyl]amino]phenylmethylene] -2-oxo-,methylester, (3Z)-, ethanesulfonate (1 : 1) and is structurally represented by compound of Formula I.

Formula I

Nintedanib is marketed in the United States under the trade name OFEV and is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Nintedanib was first described and claimed in U.S. Pat.No. 6,762, 180 and EP 1224 170. These patents disclose a process for the preparation of Nintedanib as depicted in scheme I given below:

U.S.Pat.No. 8,067,617 discloses a process for the preparation of Nintedanib intermediate Enolindole derivative), which is shown in the scheme-II given below:

Scheme-II

U.S.Pat. No. 7,119,093 discloses Nintedanib monoethanesulphonate in crystalline form characterised by X-ray powder diffraction pattern having 2Θ values at 7.70, 8.78, 9.47, 9.82, 11.59, 11.93, 13.15, 13.69, 14.17, 16.32, 16.72, 16.92, 17.43, 17.77, 18.58, 18.81, 19.03, 19.73, 19.87, 20.03, 20.61, 20.83, 21.26, 21.76, 22.05, 22.19, 22.57, 23.10, 23.81, 24.69, 24.78, 24.91, 25.42, 26.24, 26.91, 27.19, 27.61, 27.95, 28.71, 29.25.

Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint and solid state NMR spectrum. One polymorph may give rise to thermal behaviour different from that of another polymorph. Thermal behaviour can be measured in the laboratory by such techniques as capillary melting point, thermo gravimetric analysis (“TGA”) and differential scanning calorimetry (“DSC”), which have been used to distinguish polymorphic forms.

The differences in the physical properties of different polymorphs results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular Formula yet having distinct advantageous physical properties compared to other polymorphs of the same composition or complex. Hence there remains a need for polymorphic forms which have properties suitable for pharmaceutical processing on a commercial scale.

Considering the importance of Nintedanib, there exists a need to develop an alternate and improved process for the preparation of Nintedanib with better yield. Further, the process involved should be simple, convenient and cost-effective for large scale production. The inventors of the present invention during their continuous efforts also developed a novel high melting stable polymorphic form of Nintedanib ethanesulfonate.

EXAMPLES

Example 1: Process for the preparation of Nintedanib Monoethane Sulfonate:

Step-1: Preparation of methyl-3-(hydroxy(phenyl)methylene)-2-oxoindoline-6-carboxylate: To the suspension of methyl 2-oxoindoline-6-carboxylate (50 gm, 0.261 mol) in IPA (350 ml) was added slowly SMO-powder (33.8 gm, 0.626 mol) and stirred for about 15 min. Benzyl chloride (44 g, 0.313 mol) was added after completion of the reaction at a reaction temperature of -5 to -10°C for about 5hrs. The reaction mixture was quenched into ice-water (700 ml) and acidified with Cone. HC1 (2.0-2.5 ml). Filtered the reaction mixture, washed with water (2X100 ml) and dried the precipitate to obtain crude product which can be recrystallized from acetonitrile (28 ml) to obtain methyl-3-(hydroxy(phenyl)methylene)-2- oxoindoline-6-carboxylate pure crystalline solid (32 gm) (61%) (HPLC purity >97%). The filtrate was evaporated in vacuum to give unreacted methyl 2-oxoindoline-6-carboxylate. MR: 216-223°C; IR (KBr, cm“1): 3178, 1711, 1651; 1H-NMR (400 MHz, DMSO): δ 3.80 (s, 3H), 7.17 (s, 1H), 7.28-7.31 (m, 2H), 7.46-7.50 (m, 3H), 7.72 (d, 2H, J = 6.0 Hz), 9.52 (s, 1H), 11.53 (s, 1H); 13C-NMR (100 MHz, DMSO): δ 22.12, 52.41, 101.13, 111.13, 119.23, 123.06, 126.65, 127.06, 128.65, 129.21, 132.26, 134.47, 136.99, 166.58, 172.52 and 175.80; MS: m/z 294 [M]“1

Step-2: Preparation of methyl-3-(acetoxy(phenyl)methylene)-l-acetyl-2-oxoindoline-6-carboxylate (Acetyl derivative):

To the suspension of methyl-3-(hydroxy(phenyl)methylene)-2-oxoindoline-6-carboxylate (45 gm, 0.1512 mol) in acetic anhydride (300 ml) was added pyridine (4.5g) slowly (drop-wise) and stirred the reaction at temperature of 0-5°C for about30 min. After completion of the reaction raised the temperature of the reaction mass to 75-80°C and stirred for about lhr. Cooled the reaction mass and stirred for about 30 min at 25-28°C, filtered, washed with hexane (100ml) and dried the precipitate to obtain methyl-3-(acetoxy(phenyl)methylene)-l-acetyl-2-oxoindoline-6-carboxylate.

MR: 226-229°C; IR (KBr, cm“1): 3413, 1771, 1743, 1717, 1640; 1H-NMR (400 MHz, CDC13): δ 2.38 (s, 3H), 2.62 (s, 3H), 3.92 (s, 3H), 7.44 (m, 3H), 7.62 (d, 2H, J = 7.004 Hz), 7.68 (d, 1H, J = 8.12 Hz), 7.91 (d, 1H, J = 8.0 Hz), 8.90 (s, 1H); 13C-NMR (100 MHz, CDC13): δ 21.08, 21.38, 26.96, 52.25, 52.34, 115.17, 117.18, 121.33, 122.77, 125.82, 126.19, 126.56, 128.15, 128.87, 129.27, 129.34, 130.81, 130.90, 131.47, 131.82, 132.80, 138.55, 160.85, 165.95, 166.38, 166.42, 167.01, 170.67 and 170.76; MS: m/z 380 [M]+1.

Step-3: Preparation of methyl- l-acetyl-3-(((4-(2-chloro-N-methylacetamido)phenyl)amino) (phenyl)methylene)-2-oxoindoline-6-carboxylate) (Chloroacetyl derivative) :

Suspension of methyl-3-(acetoxy(phenyl)methylene)- l-acetyl-2-oxoindoline-6-carboxylate (Acetyl derivative) (49gm, 0.129mol) and N-(4-aminophenyl)-2-chloro-N-methylacetamide(25.66gm, 0.129 mol) in a mixture of methanol (350 ml) and DMF (88 ml) was heated to 60-65°C stirred for about 12hr at the same temperature. After completion of the reaction cooled the reaction mass to room temperature and stirred for about 30min. Filtered the reaction mixture, washed with methanol (2X50ml) and dried the precipitate to obtainmethyl-l-acetyl-3-(((4-(2-chloro-N-ethylacetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate).

MR: 247-250°C; IR (KBr, cm“1): 3432, 1712, 1675, 1591; 1H-NMR (400 MHz, DMSO): δ 2.74 (s, 3H), 3.11 (s, 3H), 3.78(s, 3H), 3.87 (s, 2H), 5.75 (d, 1H, J = 8.08 Hz), 7.01 (d, 2H, J = 7.96 Hz), 7.22 (d, 2H, J = 6.08Hz), 7.36 (d, 1H, J = 8.48 Hz), 7.46 (d, 2H, J = 7.24 Hz), 7.54-7.64 (m, 3H), 8.74 (s, 1H0, 11.92 (s, 1H), 13C-NMR (100MHz, DMSO): δ 27.17, 37.76, 42.48, 52.40, 96.38, 116.17, 117.59, 124.80, 125.33, 125.68, 128.09, 129.00, 130.10, 131.35, 131.97, 134.05, 160.93, 165.63, 166.68, 168.49 and 171.28; MS: m/z 518 [M]+1 and 520 [M]+1.

Step-4: Preparation of (Z)-methyl-3-(((4-(N-methyl-2-(4-methylpiperazin-lyl)acetamide) phenyl) amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate (Nintedanib free base):

Suspension of methyl- l-acetyl-3-(((4-(2-chloro-N-methylacetamido)phenyl)amino) (phenyl)methylene)-2-oxoindoline-6-carboxylate)(40 gm, 0.077ml) and N-methylpiperidine (23.24 gm, 0.232 mol) in a mixture of DMF (160 ml) was heated to a reaction temperature of 45-50°C for about l-2hrs. The reaction mixture was quenched into ice-water (1.6 Lt) and stirred for about lhr at 15-20°C. Filtered the reaction mixture mass washed with water and dried the precipitate to obtain crystalline crude solid (36 gm). Purified with acetonitrile to obtain Nintedanib free base (34 gm) as a yellow crystals (93.74%) (HPLC purity: >98%). MR: 240-246°C; IR (KBr, cm“1): 3559, 3455, 2940, 2810, 1711, 1657; 1H-NMR (400 MHz, DMSO): δ 2.09 (s, 3H), 2.17 (s, 8H), 2.68 (s, 2H), 3.05 (s, 3H), 3.76 (s, 3H), 5.80 (d, 1H, J = 7.56 Hz), 6.86 (d, 2H, J = 6.72 Hz), 7.11 (d, 1H, J = 6.48 Hz), 7.17 (d, 2H, J = 7.68 Hz), 7.42-7.57 (m, 6H), 10.98 (s, 1H), 12.23 (s, 1H) ; 13C-NMR (100MHz, DMSO): δ 37.17, 46.18, 52.24, 52.79, 55.05, 59.68, 98.10, 109.94, 117.75, 121.96, 124.29, 124.52, 128.06, 128.90, 129.40, 129.92, 130.91, 132.50, 136.72, 140.66, 158.81, 166.84, 169.04 and 170.66; MS: m/z 540 [M]+1.

Step-5: Preparation of (Z)-methyl-3-(((4-(N-methyl-2-(4-methylpiperazin-lyl)acetamide) phenyl) amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethane sulfonate salt:

Suspension of (Z)-methyl-3-(((4-(N-methyl-2-(4-methylpiperazin-l-yl)acetamide)phenyl) amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate (36 gm, 0.066 mol) in methanol (237 ml) and water (2.88 ml)was heated to 60-65°C and aq. ethane sulfonic acid was added to the reaction mixture. The resulting solution was cooled to 50°C, seeds diluted with isopropanol (237 ml) was added. The reaction mixture was cooled at 0°C for lhr. Filtered the precipitate, washed with mixture of methanol and isopropanol (50 ml), dried to obtain crude Nintedanib monoethane sulfonate (36.6 gm) and crystallized from methanol (5 Vol) to

obtained pure Nintedanib monoethane sulfonate salt as yellow crystals (33 gm) (80%) (HPLC purity >99%).

DSC: 298°C; IR (KBr, cm-1): 3321, 3273, 1710, 1652, 1615, 1515, 1435, 1378, 1289, 1209, 1161, 1087; 1H-NMR (400 MHz, DMSO): δ 1.08 (t, 3H, J = 7.31 Hz), 2.41-2.47 (q, 2H), 2.50-3.16 (broad m, 13H), 3.37 (s, 3H), 3.76 (s, 3H), 5.82 (d, 1H, J = 7.88Hz), 6.87 (d, 2H, J = 7.36 Hz), 7.14-7.20 (m, 3H), 7.49 (s, 1H), 7.49 (d, 2H, J = 6.68 Hz), 7.56-7.63 (m, 3H), 9.45 (s, 1H), 10.99 (s, 1H), 12.25 (s, 1H), 13C-NMR (100 MHz, DMSO): δ 37.15, 42.79, 45.65, 49.40, 52.26, 53.10, 58.04, 98.25, 110.01, 117.78, 121.97, 124.32, 124.59, 128.27, 128.90, 129.36, 130.00, 131.00, 132.52, 136.79, 137.93, 140.00, 158.66, 166.85, 168.47 and 170.65; MS: m/z 540[M]+1.

Example 2: Process for the preparation of Polymorph Form S of Nintedanib monoethanesulf onate :

Crude Nintedanib monoethane sulfonate was dissolved in methanol and heated to 60-64°C for about 15 min. After completion of the reaction cooled to room temperature for about lhr. Filtered the precipitate, washed with mixture of methanol (20ml) and isopropanol (30 ml) and dried to obtain pure crystalline solid (28 gm) (yield: 93.3%) with HPLC purity 99.72% and individual impurities 0.09%, 0.02% and 0.04%.

SUVEN, Chief executive and chairman Venkat Jasti

//////////WO2016178064,  POLYMORPH,  NINTEDANIB ETHANESULPHONATE, PROCESSES,  INTERMEDIATES, suven, new patent

It's only fair to share...Flattr the authorPin on PinterestEmail this to someone
Buffer this pageDigg thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInShare on YummlyShare on VKShare on RedditShare on StumbleUponPrint this pageShare on Tumblr

Leave a Reply

Your email address will not be published. Required fields are marked *